Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:1051  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 


 
   Table of Contents     
LETTER TO EDITOR  
Year : 2014  |  Volume : 6  |  Issue : 2  |  Page : 90-91
Antimicrobial susceptibility pattern of Burkholderia cepacia isolates from patients with malignancy


1 Department of Laboratory Medicine, Delhi State Cancer Institute, New Delhi, India
2 Department of Clinical Oncology, Delhi State Cancer Institute, New Delhi, India

Click here for correspondence address and email

Date of Web Publication7-May-2014
 

How to cite this article:
Roy P, Ahmed NH, Biswal I, Grover R K. Antimicrobial susceptibility pattern of Burkholderia cepacia isolates from patients with malignancy. J Global Infect Dis 2014;6:90-1

How to cite this URL:
Roy P, Ahmed NH, Biswal I, Grover R K. Antimicrobial susceptibility pattern of Burkholderia cepacia isolates from patients with malignancy. J Global Infect Dis [serial online] 2014 [cited 2019 Dec 10];6:90-1. Available from: http://www.jgid.org/text.asp?2014/6/2/90/132064


Dear Editor,

We isolated Burkholderia cepacia from blood and sputum samples of cancer patients having febrile neutropenia. B. cepacia was identified using Gram-negative GN REF 21341 identification card in automated VITEK ® 2 Compact (C) system (Biomeriux, North Carolina/USA). Antibiotic susceptibility results were expressed as susceptible, intermediate or resistant according to the criteria of the Clinical Laboratory Standards Institute M100-S23 (2013). [1]

B. cepacia was isolated from blood samples collected aseptically from five patients suffering from non-Hodgkin's lymphoma, renal cell carcinoma, carcinoma cecum with liver metastasis, acute myeloid leukemia and periampullary carcinoma; and from good quality sputum sample of a patient suffering from carcinoma lung. Detailed clinical history along with informed consent regarding possible publication was taken from all the patients. All the isolates of B. cepacia were resistant to aminoglycoside antibiotics and ciprofloxacin; and were sensitive to co-trimoxazole, meropenem, piperacillin, piperacillin-tazobactam and cefepime. Five were susceptible to ceftazidime also.

The 2010 Sanford Guide recommends co-trimoxazole as the treatment of choice for this infection. In addition, it lists 5 antibiotics to which more than 60% of clinical isolates of B. cepacia are susceptible or that are clinically effective : m0 eropenem, ceftazidime, ceftibuten, chloramphenicol and trimethoprim. [2] Since myelosuppression is a known side-effect of co-trimoxazole, it could not be used in our patients already having neutropenia. Adverse reactions are also more common with meropenem compared to piperacillin-tazobactam. Hence our patients were treated with intravenous piperacillin-tazobactam. The patients recovered clinically and repeat blood and sputum cultures were negative.

Over the past few decades, Burkholderia spp. has become an emerging opportunistic pathogen, most commonly reported in patients suffering from cystic fibrosis. [3] However, it is not commonly encountered in immune-suppressed oncology patients despite their compromised state and propensity for acquiring infections caused by Gram-negative pathogens. [4] There are few reports available regarding infections due to Burkholderia in the general oncology population. In general, Burkholderia manifests innate resistance to aminoglycoside antibiotics and widespread resistance to many beta-lactam agents, including extended-spectrum penicillins such as piperacillin and the 4 th generation cephalosporin cefepime. [2] However, in our study we found that all the isolates were uniformly susceptible to piperacillin, piperacillin-tazobactam and cefepime. So the antibiogram of Burkholderia spp. isolated from our cancer patients, by retaining susceptibility to these three antibiotics, seemed to be slightly different from those isolated from other cases. Similar findings were reported in a study by Heo et al. [5] They described an outbreak of Burkholderia stabilis in eight patients with underlying malignancies of acute lymphoblastic leukemia or acute myeloid leukemia at a university teaching hospital in Korea. Interestingly, the strains of B. stabilis isolated from this study were susceptible to a wider range of antibiotics, including piperacillin/tazobactam and cefepime, an uncommon occurrence for patients infected with Burkholderia spp.

Our findings indicate that Burkholderia spp. isolated from cancer patients may manifest an antibiogram different from that usually observed, by retaining susceptibility to more number of antibiotics especially to piperacillin-tazobactam and cefepime.

 
   References Top

1.Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 23 rd Informational Supplement. Wayne: CLSI; 2013.  Back to cited text no. 1
    
2.Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS. The Sanford Guide to Antimicrobial Therapy. 40 th ed. Sperryville, VA: Antimicrobial Therapy, INC.; 2010.  Back to cited text no. 2
    
3.Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: Epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect 2010;16:821-30.  Back to cited text no. 3
    
4.Abe K, D'Angelo MT, Sunenshine R, Noble-Wang J, Cope J, Jensen B, et al. Outbreak of Burkholderia cepacia bloodstream infection at an outpatient hematology and oncology practice. Infect Control Hosp Epidemiol 2007;28:1311-3.   Back to cited text no. 4
    
5.Heo ST, Kim SJ, Jeong YG, Bae IG, Jin JS, Lee JC. Hospital outbreak of Burkholderia stabilis bacteraemia related to contaminated chlorhexidine in haematological malignancy patients with indwelling catheters. J Hosp Infect 2008;70:241-5.  Back to cited text no. 5
    

Top
Correspondence Address:
Dr. Nishat Hussain Ahmed
Department of Laboratory Medicine, Delhi State Cancer Institute, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-777X.132064

Rights and Permissions




 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1870    
    Printed29    
    Emailed1    
    PDF Downloaded30    
    Comments [Add]    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008